Home › Trevena Announces Positive Results From Phase 2b Study Of TRV130 In Acute Postoperative Pain
 

Keywords :   


Trevena Announces Positive Results From Phase 2b Study Of TRV130 In Acute Postoperative Pain

2015-09-02 07:04:14| drugdiscoveryonline News Articles

Trevena, Inc., a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors (GPCRs), recently announced positive data from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of TRV130 in moderate to severe acute postoperative pain after abdominoplasty surgery

Tags: results study positive phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Farm Progress America, May 20, 2024
20.05Farm Progress America, May 20, 2024
20.05Ryanair profits surge after fares climb by 20%
20.05Vidzemes TV expands with PlayBox Neo Channel-in-a-Box playout
20.05ocilion enhances user experience with Simply.TV metadata
20.05Vantiva RDK device shipments exceed 125 million
20.05VinFast first with Sony Pictures in-car service
20.05LG Ad Solutions to adopt Unified ID 2.0
More »